Inhibition of Copper Transporter-1 by Ammonium Tetrathiocarbolybdate in the Treatment of Pancreatic Cancer

ZHAO Ya-nan, CHEN Li-hong, YANG Xiao-long, DONG Jing-ying, WU Wen-bing, CHEN Dan, GENG Rui-man, KE Neng-wen, LIU Ji

Abstract

To examine copper transporter 1 (CTR1) expression in pancreatic carcinoma cells, orthotopic xenograft pancreatic tumor model and clinical samples, and verify the effect of copper chelating agent ammonium tetrathiomolybdate (TM) regulate the expression of CTR1 in pancreatic carcinoma cells and the inhibition of pancreatic carcinoma.  Methods  The expressions of copper transporter CTR1 and antioxidant protein 1 (ATOX1) in 22 clinical pancreatic ductal carcinoma and paracancer tissues 0.5-1 cm away from the tumor were measured by immunohistochemistry (IHC). PANC-1 cells were used to construct 5 orthotopic xenograft pancreatic tumor of nude mice models. Pancreatic cancer tissues and corresponding normal pancreatic tissues were collected, and the expressions of CTR1 and ATOX1 were detected by IHC and compared with clinical tissues. The proliferation of pancreatic carcinoma cells PANC-1 treated with 10, 30, 50, 100 μmol/L TM for 24 h, 48 h, 72 h was measured by CCK8 assay. The migration abilities of PANC-1 cells treated with 50 μmol/L TM for 24 h, 48 h were detected by scratch test. The expressions of CTR1, vascular endothelial growth factor (VEGF) and CyclinD1 proteins in PANC-1 cells treated with 10, 30, 50, 100 μmol/L TM for 48 h were measured by Western blot. Then the subcutaneous tumor-bearing model of nude mice were established with PANC-1 cells, and the growth of tumor was observed after oral administration of 0.3 mg/d and 1.0 mg/d of TM, respectively.  Results  The immunohistochemical results indicated that 19 of the 22 clinical pancreatic ductal cancer tissues of carcinoma patients had high expression of CTR1, and the same high expression of CTR1 was found in the orthotopic transplanted tumor tissues of PANC-1 nude mice. The proliferation inhibition of PANC-1 cells increased with the concentration of TM increased and the treatment time prolonged. The expressions of intracellular CTR1, VEGF and CyclinD1 all decreased with the concentration of TM increased. The cell migration ability decreased after the PANC-1 cells treated with TM. The tumor growth of PANC-1 tumor-bearing nude mice was inhibited after different doses of TM were delivered. The reduction in tumor volume and weight was more pronounced in the high-dose TM group (P<0.05).  Conclusion  The expression of CTR1 is abnormally elevated in pancreatic carcinoma, and treatment with copper chelating agent for this target may help to inhibit pancreatic carcinoma.

 

Keywords: Pancreatic cancer, Copper transporter 1, Ammonium tetrathiomolybdate

 

Full Text:

PDF


References


SIEGEL R L， MILLER K D， JEMAL A. Cancer statistics, 2018. CA Cancer J Clin，2018，68(1): 7–30.

KLIMCZAK M， DZIKI A， KILANOWICZ A， et al. Concentrations of cadmium and selected essential elements in malignant large intestine tissue. Prz Gastroenterol，2016，11(1): 24–29.

LENER M R， SCOTT R J， WIECHOWSKA-KOZLOWSKA A， et al. Serum concentrations of selenium and copper in patients diagnosed with pancreatic cancer. Cancer Res Treat，2016，48(3): 1056–1064.

ISHIDA S， ANDREUX P， POITRY-YAMATE C， et al. Bioavailable copper modulates oxidative phosphorylation and growth of tumors. Proc Natl Acad Sci U S A，2013，110(48): 19507–19512.

FINNEY L， VOGT S， FUKAI T， et al. Copper and angiogenesis: unravelling a relationship key to cancer progression. Clin Exp Pharmacol Physiol，2009，36(1): 88–94.

GUPTE A， MUMPER R J. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev，2009，35(1): 32–46.

CHISHOLM C L， WANG H， WONG A H， et al. Ammonium tetrathiomolybdate treatment targets the copper transporter ATP7A and enhances sensitivity of breast cancer to cisplatin. Oncotarget，2016，7(51): 84439–84452.

YU Z， ZHOU R， ZHAO Y， et al. Blockage of SLC31A1-dependent copper absorption increases pancreatic cancer cell autophagy to resist cell death. Cell Prolif， 2019， 52(2): e12568[2020-03-05]. https://doi.org/ 10.1111/cpr.12568.

KUO M T， FU S， SAVARAJ N， et al. Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Res，2012，72(18): 4616–4621.

DOS SANTOS N V， MATIAS A C， HIGA G S， et al. Copper uptake in mammary epithelial cells activates cyclins and triggers antioxidant response. Oxid Med Cell Longev， 2015， 2015: 162876[2020-03-05].https://doi.org/10.1155/2015/162876.

YANG N， YAO N， LIAO X， et al. Effects of metal ions on the structure and activity of a human anti-cyclin D1 single-chain variable fragment AD5. Mol Med Rep，2017，16(2): 1314–1320.

URSO E， MAFFIA M. Behind the link between copper and angiogenesis: established mechanisms and an overview on the role of vascular copper transport systems. J Vasc Res，2015，52(3): 172–196.

LIU X， ZHANG W， WU Z， et al. Copper levels affect targeting of hypoxia-inducible factor 1α to the promoters of hypoxia-regulated genes. J Biol Chem，2018，293(38): 14669–14677.

TISATO F， MARZANO C， PORCHIA M， et al. Copper in diseases and treatments, and copper-based anticancer strategies. Med Res Rev，2010， 30(4): 708–749.

SAFI R， NELSON E R， CHITNENI S K， et al. Copper signaling axis as a target for prostate cancer therapeutics. Cancer Res，2014，74(20): 5819–5831.

BARRESI V， TROVATO-SALINARO A， SPAMPINATO G， et al. Transcriptome analysis of copper homeostasis genes reveals coordinated upregulation of SLC31A1,SCO1, and COX11 in colorectal cancer. FEBS Open Bio，2016，6(8): 794–806.


Refbacks

  • There are currently no refbacks.